Progyny, Inc. PGNY
NASDAQ · United States · Commercial Services
$25.19+0.40 (+1.61%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Progyny has delivered a mixed ride for shareholders, with the stock climbing over the past year but still showing a steep decline over five years. This puts a sharper spotlight on what investors are really paying for its earnings today. With that backdrop, the key issue is whether the current share price around US$27 fairly reflects the company’s profit engine. Over the past 5 years, Progyny’s share price has fallen 57.5%, which raises the question of whether the market is reassessing how...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.